Magic mushroom compound psilocybin shows ‘promise’ in depression
Researchers from Imperial College London say compound is at least as effective as a leading antidepressant in a therapeutic setting
Read More
Tag: Centre for Psychedelic Research
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
